Odysseas Manesiotis's questions to Qiagen NV (QGEN) leadership • Q3 2024
Question
Odysseas Manesiotis asked for details on QIAstat instrument placements, including competitive wins and the mix of reagent rentals, and questioned the capital deployment strategy regarding M&A versus share buybacks.
Answer
CEO Thierry Bernard reported over 150 QIAstat placements in Q3, driven by a newly competitive menu in the U.S., with a placement-to-capital-sale mix of roughly 50/50. Regarding capital deployment, Bernard stated that QIAGEN is active on both M&A and buybacks, remaining committed to its $1 billion shareholder return plan by 2028 while actively seeking value-accretive acquisitions.